ME02908B - Supstituisani 2-alkil-1-okso-n-fenil-3-heteroaril-1,2,3,4-tetrahidroizohinolin-4-karboksamidi za antimalarijske terapije - Google Patents

Supstituisani 2-alkil-1-okso-n-fenil-3-heteroaril-1,2,3,4-tetrahidroizohinolin-4-karboksamidi za antimalarijske terapije

Info

Publication number
ME02908B
ME02908B MEP-2017-250A MEP2017250A ME02908B ME 02908 B ME02908 B ME 02908B ME P2017250 A MEP2017250 A ME P2017250A ME 02908 B ME02908 B ME 02908B
Authority
ME
Montenegro
Prior art keywords
tetrahydroizohinoline
antimalary
heteroaryl
oxo
therapy
Prior art date
Application number
MEP-2017-250A
Other languages
German (de)
English (en)
French (fr)
Unknown language (me)
Inventor
Rodney Kiplin Guy
Fangyi Zhu
Wendyam Armand Guiguemde
David Floyd
Spencer Knapp
Philip Stein
Steve Castro
Original Assignee
Medicines For Malaria Venture Mmv
St Jude Childrens Res Hospital
Univ Rutgers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicines For Malaria Venture Mmv, St Jude Childrens Res Hospital, Univ Rutgers filed Critical Medicines For Malaria Venture Mmv
Publication of ME02908B publication Critical patent/ME02908B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MEP-2017-250A 2011-08-25 2012-08-24 Supstituisani 2-alkil-1-okso-n-fenil-3-heteroaril-1,2,3,4-tetrahidroizohinolin-4-karboksamidi za antimalarijske terapije ME02908B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161527594P 2011-08-25 2011-08-25
PCT/IB2012/054305 WO2013027196A1 (en) 2011-08-25 2012-08-24 Substituted 2-alkyl-1-oxo-n-phenyl-3-heteroaryl-1,2,3,4- tetrahydroisoquinoline-4-carboxamides for antimalarial therapies
EP12772470.6A EP2748147B1 (en) 2011-08-25 2012-08-24 Substituted 2-alkyl-1-oxo-n-phenyl-3-heteroaryl-1,2,3,4-tetrahydroisoquinoline-4-carboxamides for antimalarial therapies

Publications (1)

Publication Number Publication Date
ME02908B true ME02908B (me) 2018-10-20

Family

ID=47018313

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2017-250A ME02908B (me) 2011-08-25 2012-08-24 Supstituisani 2-alkil-1-okso-n-fenil-3-heteroaril-1,2,3,4-tetrahidroizohinolin-4-karboksamidi za antimalarijske terapije

Country Status (19)

Country Link
US (1) US9416124B2 (enExample)
EP (1) EP2748147B1 (enExample)
JP (1) JP6035334B2 (enExample)
CN (1) CN103930404B (enExample)
BR (1) BR112014004437B1 (enExample)
CA (1) CA2846507C (enExample)
CY (1) CY1119748T1 (enExample)
DK (1) DK2748147T3 (enExample)
ES (1) ES2644082T3 (enExample)
HR (1) HRP20171567T1 (enExample)
HU (1) HUE034721T2 (enExample)
LT (1) LT2748147T (enExample)
ME (1) ME02908B (enExample)
PL (1) PL2748147T3 (enExample)
PT (1) PT2748147T (enExample)
RS (1) RS56544B1 (enExample)
SI (1) SI2748147T1 (enExample)
SM (1) SMT201700528T1 (enExample)
WO (1) WO2013027196A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3672597A4 (en) * 2017-08-21 2021-09-22 Navigen, Inc. ARF6 INHIBITORS AND RELATED PROCEDURES
EP3892332A1 (en) 2020-04-09 2021-10-13 University Of Kentucky Research Foundation New anti-malarial agents
EP4322949B1 (en) 2021-04-15 2025-03-19 RDP Pharma AG Isoquinoline derivatives for use as antiviral and antitumour agents
KR20220142828A (ko) * 2021-04-15 2022-10-24 발도스판 게엠바하 E7 분해제
EP4074314A1 (en) 2021-04-15 2022-10-19 Valdospan GmbH Isoquinoline derivatives for use as antiviral and antitumour agents
EP4605376A1 (en) 2022-10-17 2025-08-27 RDP Pharma AG Isoquinoline derivatives as protein degraders, e7 degraders, antivirals, tumor therapeutics and immune suppressives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639761A (en) * 1994-02-14 1997-06-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antimalarial naphthylisoquinoline alkaloids and pharmaceutical compositions and medical uses thereof
US5409938A (en) * 1994-02-14 1995-04-25 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Antimalarial korupensamines and pharmaceutical compositions and medical uses thereof
US6921762B2 (en) * 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
WO2004004727A1 (en) 2002-07-03 2004-01-15 Axys Pharmaceuticals, Inc. 3,4-dihydroisoquinolin-1-one derivatives as inducers of apoptosis
DE10237722A1 (de) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
DE10312963A1 (de) 2003-03-24 2004-10-07 Aventis Pharma Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
MY145281A (en) 2005-03-25 2012-01-13 Glaxo Group Ltd Novel compounds
RU2302417C1 (ru) 2006-03-14 2007-07-10 Иващенко Андрей Александрович 1-оксо-3-(1н-индол-3-ил)-1,2,3,4-тетрагидроизохинолины, способы их получения, комбинаторная библиотека и фокусированная библиотека
AU2009250843A1 (en) * 2008-05-19 2009-11-26 Actelion Pharmaceuticals Ltd Tetrahydroisoquinolines as antimalarial agents
GB0820856D0 (en) * 2008-11-14 2008-12-24 Univ Leuven Kath Novel inhibitors of flavivirus replication

Also Published As

Publication number Publication date
SI2748147T1 (sl) 2017-11-30
CN103930404A (zh) 2014-07-16
HRP20171567T1 (hr) 2017-11-17
EP2748147B1 (en) 2017-08-02
US9416124B2 (en) 2016-08-16
JP2014524464A (ja) 2014-09-22
CY1119748T1 (el) 2018-06-27
WO2013027196A9 (en) 2013-04-18
RS56544B1 (sr) 2018-02-28
JP6035334B2 (ja) 2016-11-30
EP2748147A1 (en) 2014-07-02
PT2748147T (pt) 2017-11-14
WO2013027196A1 (en) 2013-02-28
CA2846507A1 (en) 2013-02-28
HK1199443A1 (en) 2015-07-03
SMT201700528T1 (it) 2018-01-11
BR112014004437A8 (pt) 2018-01-23
HUE034721T2 (hu) 2018-02-28
CN103930404B (zh) 2016-08-24
LT2748147T (lt) 2017-10-25
DK2748147T3 (da) 2017-11-13
PL2748147T3 (pl) 2018-01-31
CA2846507C (en) 2020-03-10
BR112014004437B1 (pt) 2021-12-14
ES2644082T3 (es) 2017-11-27
US20140235593A1 (en) 2014-08-21
BR112014004437A2 (pt) 2017-03-28

Similar Documents

Publication Publication Date Title
EP2762476A4 (en) 1,2,4-triazine-6-carboxamide derivative
EP2663304A4 (en) COMBINATION THERAPY
BR112013024491A2 (pt) neuroestimulador.
LT3026064T (lt) Antikūnai, skirti vėžio gydymui, ekspresuojantys klaudiną 6
CO6960518A2 (es) Conjunto de desgaste
EP2720749A4 (en) PERCUTANEOUS TIBIAL VACIMINATOR
BR112014002399A2 (pt) conjunto
PL2684880T3 (pl) Pochodna dispiropirolidyny
CO6890099A2 (es) Nuevos derivados dihidroquinolina-2-ona
DK2760886T3 (da) Immunocytokin-kombinationsterapi
EP2726095A4 (en) COMBINATION THERAPY
FI20115876A0 (fi) Yhdistelmähoito
IL229081A0 (en) Isoxazolines as therapeutic agents
BR112013030897A2 (pt) composição.
HRP20190229T1 (hr) Ormar, postupak za izradu ormara
CO6880064A2 (es) Métodos terapéuticos
PL2762466T3 (pl) Pochodna fenylu
DK2748147T3 (da) Substitueret 2-alkyl-1-oxo-n-phenyl-3-heteroaryl-1,2,3,4-tetrahydroisoquinolin-4-carboxamider til antimalaria-terapier
FI20115640A0 (fi) Yhdistelmähoito
FR2978994B1 (fr) .
DK2500470T3 (da) Hoved-arbejdsvogn
EP2736334A4 (en) DENIBULIN dihydrochloride
ES2397885B1 (es) Derivados de colismicina.
FR2973145B1 (fr) Atlas visuo-tactile.
FR2980994B1 (fr) Prehenseur multi-plaquettes.